Unlock instant, AI-driven research and patent intelligence for your innovation.

Pharmaceutical angiostatic dipeptide compositions and methods of use thereof

a technology of angiostatic dipeptide and composition, which is applied in the direction of peptide/protein ingredients, drug compositions, angiogenin, etc., can solve problems such as the problematic clinical experience of cytokine therapy, and achieve the effects of stimulating the production of immune cells, normalizing numerical relationships, and low levels of l-glu-l-trp dipeptide preventing neovascularization

Inactive Publication Date: 2006-05-04
MELMOTTE +1
View PDF1 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent text describes a method for treating various conditions involving neovascularization (the formation of new blood vessels) using a pharmaceutical preparation containing a specific dipeptide called L-Glu-L-Trp. The dipeptide has been found to inhibit the growth of new blood vessels in animal studies, and the patent aims to provide methods for treating a variety of pathologic conditions associated with neovascularization, including hemangiomas, tumors, and diabetes-related complications. The dipeptide has been found to have both immune-stimulating and angiostatic (inhibiting new blood vessel formation) activity, and the patent aims to provide methods for treating a variety of pathologic conditions associated with neovascularization.

Problems solved by technology

However, clinical experience with cytokine therapy has proven problematic due to the toxicity of certain of these compounds.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

Lack of Mutagenicity and Toxicity of L-Glu-L-Trp: Pharmacokinetics and Biodistribution

[0058] *Note that general materials and methods used in Examples, below, appear at the end of the Examples section and immediately before the citations.

Protocol A

Acute Toxicity Studies

[0059] Summary: L-Glu-L-Trp when injected im at dosages calculated to be about 10,000-times a therapeutic dosage were non toxic in mice, guinea pigs, chickens, and dogs as determined by monitoring general condition, behavior, movements, cardiac and respiratory physiology, and gross pathology.

Protocol B

Chronic Toxicity Studies

[0060] Summary: L-Glu-L-Trp when injected daily as a single im or iv for a period of 28 days was without adverse effects as determined by monitoring behavior, feeding, body weight, coat condition, mucous membranes, red and white cell blood counts, cardiac and respiratory physiology, liver and kidney function, and gross pathology. Kidney function was determined by evaluation of diuresis afte...

example 2

Inhibitory Effects of L-Glu-L-Trp on Angiogenesis in Chorioallantoic Membrane (CAM) Assays

[0062] Briefly, eight-day chicken embryos were removed from eggs and placed into sterile petri dishes. Individual filter paper disks were saturated with 7.5 μl of different stock solutions of L-Glu-L-Trp dissolved in sterile 0.14M NaCl to achieve final test concentrations of 0.001, 0.01, 0.1, 1.0, 10, 100, 500, and 1000 μg per disk. Disks were air dried and then inverted onto the surface of the respective embryos. Embryo vascularization was assessed after 48 hrs. of incubation using the grading scale summarized in TABLE 1, below.

TABLE 1Scoring of Chicken Embryo Vascularity: CAM AssayPercentageInhibition GradeDescriptionInhibition0Not visibly difference than negative0control1Slight inhibition of vessel formation252Moderate inhibition of vessel formation503Near-complete inhibition of vessel75formation4Complete inhibition of vessel formation100

[0063] In this experiment saline served as a negati...

example 3

Inhibition of Neovascularization of Lewis Carcinoma

[0065] Lewis lung carcinoma cells (5×107) when injected (0.1 ml) intradermally into both flanks of C57BL / 6 mice (day 0) produce a visible highly vascularized tumor nodules within 7 days. By excising the tumor the degree of tumor vascularity may be determined microscopically by counting the number of large vessels radiating from the tumor mass. An independent study was performed (as follows) at a GLP approved contract research organization.

[0066] Saline was used as a negative control and Cytoxan as a positive control. The positive control, Cytoxan (200 mg / kg), was administered only on day 2. Test treatments with L-Glu-L-Trp were administered im on a daily basis starting on day 1 after tumor injection and continuing for 5 days (i.e., through day 6). L-Glu-L-Trp was administered at doses of 125, 250, 500, 1000, and 2000 μg / kg / dose. The negative control, saline, was administered ip on the same daily 5 day schedule. Ten mice (20 tumors...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
weightaaaaaaaaaa
weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to View More

Abstract

Disclosed are methods of inhibiting neovascularization in a subject by administering to the subject a pharmaceutical preparation of R′-Glu-Trp-R″.

Description

[0001] This application is a continuation-in-part of copending Ser. No. 08 / 538,701, filed Oct. 3, 1995, incorporated herein by reference in its entirety.BACKGROUND OF THE INVENTION [0002] The present invention relates generally to pharmaceutical compositions containing peptides having angiostatic properties and more particularly to pharmaceutical compositions of tryptophan-containing dipeptides and methods of use thereof. [0003] Neovascularization, the genesis of new blood vessels, is triggered early in embryogenesis and also during wound healing, tissue remodeling and probably in the normal course of maintenance of the vascular system. Processes involved in neovascularization include at least endothelial cell and pericyte activation; basal lamina degradation; migration and proliferation of endothelial cells and pericytes; formation of a new capillary vessel lumen; appearance of pericytes around the new vessels; development of a new basal lamina; capillary loop formation; persistenc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/04A61K9/00A61K9/08A61K38/00A61K38/05A61K38/55A61P9/00A61P35/00C07K5/06C07K5/072
CPCA61K38/05C07K5/06034A61P35/00A61P9/00
Inventor GREEN, LAWRENCEBLASECKI, JOHN
Owner MELMOTTE